tirzepatide and general anesthesia Are Serious Anesthesia Risks of Semaglutide and Other GLP-1 Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia ASA: Hold GLP-1 Agonists Before

Zelniker et al 27 performed a meta-analysis and found that SGLT-2 inhibitors protected the kidney better than GLP-1 receptor agonists did

After 24 months semaglutide treatment, BW was 71 kg (absolute change -4 kg vs

it intersects with physiology, baseline health, and trial design

Nicotinic acetylcholine receptors: from structure to brain function

In plain terms: survodutide has promising, peer-reviewed, randomized Phase 2 human evidence in obesity and MASH, a positive but not-yet-published Phase 3 obesity topline , a solid preclinical mechanism , and no approved indication

Its dual impact on appetite and blood sugar regulation makes it a compelling option for those seeking a more comprehensive solution